2025 was a challenging year for the UK biotech sector, but it ended the year with signs of “renewed confidence,” says the BIA industry body.
Sanofi vows to stay committed to vaccines as portfolio takes a hit
Sanofi CEO Paul Hudson emphasized the company’s commitment to vaccine development in the face of an increasingly challenging sales environment and its decision to abandon



